Focusing our efforts in raising the bar for pulmonary hypertension (PH) management.
At Janssen, we are focusing our worldwide scientific and commercial expertise to help raise the bar in the management of PH. Janssen brings to the PH field a remarkable track record in scientific discovery and a deep patient-centric focus, underpinned by an open, transparent business culture.
We are committing our extensive resources and expertise to build on current PH initiatives, as well as pursuing new opportunities to improve diagnosis, access to therapy and patient outcomes. As part of one of the largest global pharmaceutical companies, with entities across the world, we are able to utilize the vast experience of our Janssen colleagues at every stage of the development process to ensure we continue to meet our overarching goal of providing access to treatments for those patients who require them most.
Our people truly understand the unmet medical needs of PH patients and the healthcare systems that serve them. Our workforce of 40,000 people, with a global reach extending to 150 countries, is helping to reach more patients worldwide.